Home » 2018 » September
Alexion to acquire Boston-based Syntimmune in $1.2bn deal

Alexion to acquire Boston-based Syntimmune in $1.2bn deal

Alexion acquisition of Syntimmune : US pharma company Alexion Pharmaceuticals has signed a deal of around $1.2 billion to acquire Syntimmune, a Boston-based clinical-stage biotech company focused on developing drugs for autoimmune diseases. Alexion Pharmaceuticals, on the other hand, is a multi-national biopharma company engaged in developing drugs to treat rare diseases. Alexion acquisition of […]

Taro scraps onychomycosis drug Novexatin deal with NovaBiotics

Taro Pharmaceutical Industries said that it has scrapped its licensing agreement with Scottish biotech company NovaBiotics for Novexatin after the investigational onychomycosis drug failed to meet its objective in a clinical trial. In May, a phase 2b study for Novexatin failed to meet its primary goal by not demonstrating superiority over the placebo, which led […]

Continue reading …
Trovagene updates on acute myeloid leukemia trial for Onvansertib

Trovagene, a California-based cancer research company, said that it has wrapped up the second dosing cohort of the Onvansertib-decitabine combination, in a phase 1b/2 acute myeloid leukemia trial. Onvansertib is said to be a highly-selective oral Polo-like Kinase 1 (PLK1) inhibitor. Designed to be orally administered, Onvansertib has a 24-hour drug half-life. According to Trovagene, […]

Continue reading …
Lilly scores US FDA approval for migraine drug Emgality

Lilly migraine drug Emgality FDA approval : Eli Lilly and Company (Lilly) has bagged approval from the US Food and Drug Administration (FDA) for Emgality (galcanezumab-gnlm) 120 mg injection as a prophylactic therapy for migraine in adults. Emgality, which is a calcitonin gene-related peptide (CGRP) antagonist, comes with a once-monthly, self-administered, subcutaneous injection. The Lilly […]

Continue reading …
Small Lifestyle Changes and The Compound Effect on Heart Risk in Women

Around the world, cardiovascular disease and heart health is a topic of great importance among both men and women. A recent study published by the World Health Organization cites just under 18 million deaths due to heart disease in 2015, making up nearly 31% of all fatalities in adult populations. These statistics make cardiovascular conditions […]

Continue reading …
Almirall acquires US skin medications from Allergan for $550m

Spanish pharma company Almirall has completed its $550 million acquisition of five skin medications from Allergan’s Medical Dermatology unit in the US. The skin medications acquired by Almirall, as part of a deal signed in August 2018, are acne and dermatoses brands Aczone (dapsone), Tazorac (tazarotene), Cordran Tape (flurandrenolide), Azelex (azelaic acid). Along with them, […]

Continue reading …
Janssen depression medication esketamine nasal spray yields mixed results in phase 3 trial

Janssen Pharmaceutical Companies of Johnson & Johnson depression medication esketamine nasal spray did not meet expectations in a phase 3 trial in patients with treatment-resistant depression. The late-stage randomized trial evaluated two fixed doses of esketamine – 56 mg and 84 mg along with an oral antidepressant in comparison to placebo plus oral antidepressant. Janssen […]

Continue reading …
Research finds aspirin intake does not reduce heart attack or stroke risk

A seven-year study held in more than 19,000 older people from the US and Australia found that daily intake of aspirin daily does not cut down the chances of heart attack or stroke and neither does it have any benefit in prolonging life free of disability. The study was headed by Monash University in Australia […]

Continue reading …
Roivant launches Respivant Sciences to develop drugs for respiratory diseases

Roivant Sciences has launched a new biopharma company named Respivant Sciences which will focus on developing innovative therapeutics for serious respiratory diseases. The new biopharma company of Roivant Sciences will be headed by Bill Gerhart – CEO, Ahmet Tutuncu – Executive Vice President for Clinical and Regulatory, and Pravin Soni – Executive Vice President for […]

Continue reading …
Ajovy FDA approval : Teva’s Ajovy approved in US for migraine prevention

Ajovy FDA approval : Israeli pharma company Teva Pharmaceutical Industries has bagged the US Food and Drug Administration (FDA) approval for Ajovy (fremanezumab-vfrm) injection to be used for migraine prevention in adults. A humanized monoclonal antibody, Ajovy binds to calcitonin gene-related peptide (CGRP) ligand and prevents its binding to the receptor. Ajovy FDA approval for […]

Continue reading …
Page 1 of 41234